Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Cardiol ; 201: 107-115, 2023 08 15.
Article in English | MEDLINE | ID: mdl-37354866

ABSTRACT

We sought to assess the prognostic value of coronary computed tomographic angiography (CCTA) in patients with coronary artery bypass graft (CABG) by meta-analysis. MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Scopus were searched for relevant original articles published up to July 2021. CCTA prognostic studies enrolling patients with CABG were screened and included if outcomes included all-cause mortality or major adverse cardiac events. Maximally adjusted hazard ratios (HRs) were extracted for CCTA-derived prognostic factors. HRs were log-transformed and pooled across studies using the DerSimonian-Laird random-effects model and statistical heterogeneity was assessed using the I2 statistic. Of 1,576 screened articles, 4 retrospective studies fulfilled all inclusion criteria. Collectively, a total of 1,809 patients with CABG underwent CCTA (mean [SD] age 67.0 [8.5] years across 3 studies, 81.5% male across 4 studies). Coronary artery disease severity and revascularization were categorized using 2 models: unprotected coronary territories and coronary artery protection score. The pooled HRs from the random-effects models using the most highly adjusted study estimate were 3.64 (95% confidence interval 2.48 to 5.34, I2 = 57.8%, p <0.001; 4 studies) and 4.85 (95% confidence interval 3.17 to 7.43, I2 = 39.9%, p <0.001; 2 studies) for unprotected coronary territories and coronary artery protection score, respectively. In conclusion, in a limited number of studies, CCTA is an independent predictor of adverse events in patients with CABG. Larger studies using uniform models and endpoints are needed.


Subject(s)
Computed Tomography Angiography , Coronary Artery Disease , Humans , Male , Aged , Female , Prognosis , Retrospective Studies , Coronary Angiography/methods , Coronary Artery Bypass/adverse effects , Coronary Artery Disease/diagnostic imaging , Coronary Artery Disease/surgery , Coronary Artery Disease/etiology
2.
J Am Geriatr Soc ; 71(10): 3278-3286, 2023 10.
Article in English | MEDLINE | ID: mdl-37289174

ABSTRACT

BACKGROUND: Frailty has emerged as an important prognostic marker of increased mortality after cardiac surgery, but its association with quality of life (QoL) and patient-centered outcomes is not fully understood. We sought to evaluate the association between frailty and such outcomes in older patients undergoing cardiac surgery. METHODS: This systematic review included studies evaluating the effect of preoperative frailty on QoL outcomes after cardiac surgery amongst patients 65 years and older. The primary outcome was patient's perceived change in QoL following cardiac surgery. Secondary outcomes included residing in a long-term care facility for 1 year, readmission in the year following the intervention, and discharge destination. Screening, inclusion, data extraction, and quality assessment were performed independently by two reviewers. Meta-analyses based on the random-effects model were conducted. The evidential quality of findings was assessed with the GRADE profiler. RESULTS: After the identification of 3105 studies, 10 observational studies were included (1580 patients) in the analysis. Two studies reported on the change in QoL following cardiac surgery, which was higher for patients with frailty than for patients without. Preoperative frailty was associated with both hospital readmission (pooled odds ratio [OR] 1.48 [0.80-2.74], low GRADE level) as well as non-home discharge (pooled OR 3.02 [1.57-5.82], moderate GRADE level). CONCLUSION: While evidence in this field is limited by heterogeneity of frailty assessment and non-randomized data, we demonstrated that baseline frailty may possibly be associated with improved QoL, but with increased readmission as well as discharge to a non-home destination following cardiac surgery. These patient-centered outcomes are important factors when considering interventional options for older patients. STUDY REGISTRATION: OSF registries (https://osf.io/vm2p8).


Subject(s)
Cardiac Surgical Procedures , Frailty , Humans , Aged , Frailty/diagnosis , Quality of Life , Patient Readmission , Outcome Assessment, Health Care
3.
PLoS One ; 17(2): e0262742, 2022.
Article in English | MEDLINE | ID: mdl-35120151

ABSTRACT

BACKGROUND: Frailty has emerged as an important prognostic marker of adverse outcomes after cardiac surgery, but evidence regarding its ability to predict quality of life after cardiac surgery is currently lacking. Whether frail patients derive the same quality of life benefit after cardiac surgery as patients without frailty remains unclear. METHODS: This systematic review will include interventional studies (RCT and others) and observational studies evaluating the effect of preoperative frailty on quality-of-life outcomes after cardiac surgery amongst patients 65 years and older. Studies will be retrieved from major databases including the Cochrane Central Register of Controlled Trials, Embase, and Medline. The primary exposure will be frailty status, independent of the tool used. The primary outcome will be change in quality of life, independent of the tool used. Secondary outcomes will include readmission during the year following the index intervention, discharge to a long-term care facility and living in a long-term care facility at one year. Screening, inclusion, data extraction and quality assessment will be performed independently by two reviewers. Meta-analysis based on the random-effects model will be conducted to compare the outcomes between frail and non-frail patients. The evidential quality of the findings will be assessed with the GRADE profiler. CONCLUSION: The findings of this systematic review will be important to clinicians, patients and health policy-makers regarding the use of preoperative frailty as a screening and assessment tool before cardiac surgery. STUDY REGISTRATION: OSF registries (https://osf.io/vm2p8).


Subject(s)
Quality of Life
4.
CJC Open ; 3(12 Suppl): S102-S117, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34993440

ABSTRACT

Women with a history of hyperBtensive disorders of pregnancy (HDP) are at particularly high risk for cardiovascular disease (CVD) and CVD-related death, and certain racial and ethnic subpopulations are disproportionately affected by these conditions. We examined the use of race, ethnicity, and national origin in observational studies assessing CVD morbidity and mortality in women with a history of HDP. A total of 124 studies, published between 1976 and 2021, were reviewed. We found that white women were heavily overrepresented, encompassing 53% of all participants with HDP. There was limited and heterogeneous reporting of race and ethnicity information across studies and only 27 studies reported including race and/or ethnicity variables in at least 1 statistical analysis. Only 2 studies mentioned the use of these variables as a strength; several others (k = 18) reported a lack of diversity among participants as a study limitation. Just over half of included articles (k = 68) reported at least 1 sociodemographic variable other than race and ethnicity (eg, marital status and income); however, none investigated how they might have worked synergistically or antagonistically with race and/or ethnicity to influence participants' risk of CVD. These findings highlight significant areas for improvement in cardiovascular obstetrics research, including the need for more robust and standardized methods for collecting, reporting, and using sociodemographic information. Future studies of CVD risk in women with a history of HDP should explicitly examine racial and ethnic differences and use an intersectional approach.


Les femmes ayant des antécédents de troubles hypertensifs de la grossesse (THG) présentent un risque particulièrement élevé de maladies cardiovasculaires (MCV) et de décès liés à ces dernières, et certaines sous-populations raciales et ethniques sont touchées de manière disproportionnée par ces maladies. Nous avons examiné l'utilisation de la race, de l'ethnicité et de l'origine nationale dans les études observationnelles évaluant la morbidité et la mortalité liées aux MCV chez les femmes ayant des antécédents de THG. Un total de 124 études, publiées entre 1976 et 2021, ont été examinées. Nous avons constaté que les femmes blanches étaient fortement surreprésentées, puisqu'elles constituaient 53 % de l'ensemble des participantes atteintes de THG. Les renseignements relatifs à la race et à l'ethnicité étaient limités et hétérogènes d'une étude à l'autre, et seules 27 études ont indiqué avoir tenu compte de variables relatives à la race ou à l'ethnicité dans au moins une analyse statistique. Seules deux études ont mentionné l'utilisation de ces variables comme un point fort; plusieurs autres (k = 18) ont signalé un manque de diversité parmi les participantes comme une limite de l'étude. Un peu plus de la moitié des articles inclus (k = 68) ont fait état d'au moins une variable sociodémographique autre que la race et l'ethnicité (p. ex., l'état matrimonial et le revenu); aucun toutefois n'a étudié la manière dont ces variables auraient pu agir en synergie ou en opposition avec la race ou l'ethnicité pour influencer le risque de MCV des participantes. Ces résultats mettent en évidence des points importants à améliorer dans la recherche sur l'obstétrique cardiovasculaire, notamment la nécessité de méthodes plus fiables et normalisées en matière de collecte, de communication et d'utilisation des données sociodémographiques. Les prochaines études sur le risque de MCV chez les femmes ayant des antécédents de THG devraient examiner explicitement les différences raciales et ethniques et adopter une approche intersectionnelle.

5.
Clin Invest Med ; 42(2): E26-32, 2019 06 23.
Article in English | MEDLINE | ID: mdl-31228965

ABSTRACT

PURPOSE: Patients in cardiac intensive care units (ICU) are admitted with increasingly higher disease acuity and a larger burden of non-cardiac critical illness. Accordingly, positive inotropes are being used with increased frequency and little comparative data to support drug selection. We compared the effectiveness and safety of dobutamine and milrinone in low cardiac output states (LCOS) and/or cardiogenic shock (CS). METHODS: We performed a systematic review comparing dobutamine to milrinone on all-cause mortality, length of stay in the ICU (LOS-ICU), length of stay in hospital (LOS-H) and significant arrhythmias in hospitalized patients with LCOS and/or CS. RESULTS: We identified 11 studies that meet eligibility requirements and which were published between 2001 and 2016 and included 23,056 patients. Only one randomized clinical trial was identified, with the remaining studies comprising observational cohort studies. The primary outcome, all-cause mortality, trended towards a benefit with milrinone but did not meet pre-specified significance (OR 1.13, 95% CI 1.00-1.29, p=0.06). While LOS-ICU (mean difference -0.72, 95% CI -1.10- -0.34, p=0.0002) was shorter with dobutamine, there was no difference in LOS-H (mean difference -1.22, 95% CI -4.68 - 2.24, p=0.49). Significant arrhythmias, specifically symptomatic and/or requiring antiarrhythmic therapy, were no different between the groups (OR 1.78, 95% CI 0.85-3.76, p=0.13). CONCLUSIONS: Currently available data comparing milrinone to dobutamine in patients requiring inotropic support is limited. Dobutamine may be associated with a shorter LOS in the ICU, with a worrisome signal of increased risk of allcause mortality. Randomized data are needed to guide inotrope selection in patients with LCOS and/or CS.


Subject(s)
Dobutamine , Milrinone , Cardiac Output, Low/drug therapy , Cardiotonic Agents/therapeutic use , Dobutamine/therapeutic use , Humans , Length of Stay , Milrinone/therapeutic use , Randomized Controlled Trials as Topic
SELECTION OF CITATIONS
SEARCH DETAIL
...